Therapeutic Trial in Amyotrophic Lateral Sclerosis

Publisher Website
Google Scholar
Abstract
It has been reported that patients with amyotrophic lateral sclerosis (ALS) are deficient in exocrine secretion of the pancreas, and that treatment of ALS with large dosages of pancreatic extract and DL-alpha tocopherol (vitamin E) given with a diet high in protein and low in fat and carbohydrate beneficially modifies the course of the disease.1-3 This brief report summarizes our experience with such a treatment program given to patients with ALS who have participated in an ongoing series of drug trials over the past three years and demonstrates the merit of serial quantitative muscle testing (QMT) to evaluate the course of the patients. Methods The diagnosis of ALS was based upon the following clinical observations, which are applicable to these patients but not intended to be general criteria for diagnosing every case of ALS: (1) onset during middle-age or later of a sub-acutely progressive disorder characterized by (2) "anterior

This publication has 0 references indexed in Scilit: